Breaking Down GNI Group Ltd. Financial Health: Key Insights for Investors

Curious whether GNI Group Ltd. (2160.T) is a turnaround opportunity or a risky bet? The company reported revenue of ¥23.61 billion for FY2024 (down 9.22% year-over-year) but posted a strong quarterly rebound with Q3 2025 revenue up 30.16% and TTM revenue of ¥25.78 billion (+13.78% YoY); meanwhile the market values the business at a ¥133.32 billion market cap (stock ¥2,309.00, P/S 5.17) even as profitability faltered-operating profit plunged to ¥1.4 billion (an 89.3% decline) and net income slid to ¥977 million, EPS fell to ¥19.55 and ROE sits at -5.85%-cash dynamics are mixed with negative operating cash flow of ¥(3,164) million and free cash flow of ¥(3.03) billion offset by cash and equivalents of ¥9.93 billion yielding a net cash position of ¥4.48 billion, low leverage (debt ¥5.45 billion, debt/equity 0.13) and solid liquidity (current ratio 2.64, quick ratio 1.56); valuation metrics include a forward P/E of 17.95 and P/B of 3.57, the 52-week price is down 15.17% with beta 1.28, and growth catalysts range from analyst-forecasted revenue growth of 44.6% to late-stage programs like Etuary in Phase III-read on to unpack these figures, risks and the drivers behind GNI's next moves.

GNI Group Ltd. (2160.T) - Revenue Analysis

• Fiscal year 2024 revenue: ¥23.61 billion, down 9.22% from ¥26.01 billion in FY2023.
• Quarter (Q3 2025, ended Sep 30) revenue growth: +30.16% year-over-year.
• Trailing twelve months (TTM) revenue as of Dec 19, 2025: ¥25.78 billion, +13.78% YoY.

• The FY2024 decline (-9.22%) reflects near-term headwinds but is offset by a robust recovery into 2025, as shown by the 30.16% Q3 jump and a 13.78% TTM increase by Dec 19, 2025.
• Revenue per employee (¥29.73M) and headcount (867) indicate operational scale; monitoring productivity trends alongside margins is essential.
• A P/S of 5.17 and market cap of ¥133.32B imply the market prices in future growth - validate expectations against earnings, cash flow, and margin expansion.

GNI Group Ltd. (2160.T) Profitability Metrics

FY2024 showed a pronounced deterioration in GNI Group Ltd.'s earnings and cash-generation ability, with sharp year-on-year declines across operating profit, net income, EPS and comprehensive income, alongside negative operating and free cash flows and a negative ROE.

• Operating profit (FY2024): ¥1,400 million - down 89.3% vs FY2023.
• Net income (FY2024): ¥977 million - down 87.9% vs FY2023.
• EPS (FY2024): ¥19.55 - from ¥169.50 in FY2023.
• Return on equity (ROE, FY2024): -5.85%.
• Operating cash flow: negative (FY2024).
• Free cash flow: negative (FY2024).
• Comprehensive income (FY2024): ¥2,268 million - down 78.7% vs FY2023.

Key implications for investors:

• The collapse in operating profit and EPS signals material margin pressure or one-off charges in FY2024.
• Negative operating and free cash flows raise short-term liquidity and funding concerns despite positive net income.
• A negative ROE (-5.85%) suggests returns to shareholders were impaired relative to equity base in FY2024.
• Sharp drop in comprehensive income (-78.7%) reduces the company's overall total-return profile for the year.

Further context and shareholder activity can be found here: Exploring GNI Group Ltd. Investor Profile: Who's Buying and Why?

GNI Group Ltd. (2160.T) - Debt vs. Equity Structure

• Total debt decreased by ¥0.44 billion year-over-year to ¥5.45 billion as of March 2025.
• Cash & cash equivalents of ¥9.93 billion produced a net cash position of ¥4.48 billion, providing balance-sheet flexibility.
• Debt-to-equity at 0.13 signals conservative leverage relative to peers in the sector.
• Total liabilities of ¥32.23 billion versus total equity of ¥36.45 billion yield an equity ratio near 50%, underlining a solid equity cushion.
• Total assets grew to ¥67.72 billion (FY2024) from ¥64.27 billion (FY2023), reflecting balance-sheet expansion.

GNI Group Ltd. (2160.T) - Liquidity and Solvency

• Current ratio: 2.64 - indicates short-term assets are 2.64x short-term liabilities, a generally comfortable coverage level.
• Quick ratio: 1.56 - excludes inventories and still exceeds 1.0, suggesting sufficient liquid assets to meet immediate obligations.

• Despite healthy ratios (current and quick), negative operating cash flow (¥(3,164) million) and negative free cash flow (¥(3.03) billion) indicate earnings are not translating into cash - raising refinancing or working-capital risk.
• An interest coverage ratio of -1.53 signals operating losses relative to interest expense; debt servicing depends on non-operating resources or new financing.
• Total liabilities exceed cash and short-term receivables by ¥15.9 billion, highlighting potential liquidity gaps if short-term funding is required.
• Management focus areas likely include restoring positive operating cash flow, reducing leverage, and improving EBITDA relative to interest costs.

GNI Group Ltd. (2160.T) - Valuation Analysis

Overview of market pricing and valuation multiples for GNI Group Ltd. (2160.T) as of December 19, 2025, providing investors with the key metrics used to assess relative value and market expectations.

• Market capitalization: ¥133.32 billion (stock price ¥2,309.00).
• Price-to-Sales (P/S): 5.17 - market values revenue at roughly 5.17x trailing sales.
• Price-to-Book (P/B): 3.57 - equity is priced at 3.57x book value.
• Enterprise Value (EV): ¥134.05 billion - slightly below market cap.
• Forward Price-to-Earnings (P/E): 17.95 - market-implied earnings growth expectations.
• 52-week performance: -15.17%; Beta: 1.28 - higher volatility than market average.

Practical considerations for investors:

• Relative valuation: P/S of 5.17 and P/B of 3.57 place GNI above many defensive peers-reflects growth expectations or pricing premium.
• Forward P/E of 17.95 indicates the market is discounting future earnings growth but not an aggressive multiple for a growth company.
• EV slightly lower than market cap suggests limited net debt or modest cash holdings; verify balance-sheet cash/debt to confirm.
• Negative 52-week return and beta 1.28 imply elevated downside risk during market drawdowns; consider volatility in position sizing.

Further context on corporate purpose and strategic direction is available here: Mission Statement, Vision, & Core Values (2026) of GNI Group Ltd.

GNI Group Ltd. (2160.T) - Risk Factors

• Profitability shock: operating profit fell by 89.3% in FY2024, signaling margin compression and/or one-off losses.
• Negative cash generation: operating cash flow was ¥(3,164) million in FY2024, and free cash flow is also negative, exacerbating liquidity pressure.
• Interest coverage stress: an interest coverage ratio of -1.53 indicates operating income is insufficient to cover interest expenses.
• Share-price weakness: the stock is down 15.17% over the last 52 weeks, reflecting investor concern about near-term prospects.
• Debt context: a low debt-to-equity ratio of 0.13 reduces leverage risk but, when combined with persistent negative cash flows, raises questions about sustainable operations and funding sources.

GNI Group Ltd. (2160.T) - Growth Opportunities

• Analyst growth projection: consensus forecast of 44.6% compound annual revenue growth (next 12-24 months), signaling expectations for rapid expansion of commercial or milestone-driven revenues.
• Valuation signal: forward P/E of 17.95, reflecting investor anticipation of improving profitability as development-stage assets progress toward commercialization or licensing.

• Etuary (Phase III) - a high-impact near-term value driver: progression through Phase III materially de-risks commercialization potential for CT‑ILD, a segment with limited approved therapies and significant unmet need.
• Pipeline diversification - multiple programs in pulmonary (radiation pneumonitis) and renal (diabetic nephropathy) indications reduce single‑asset risk and increase optionality for partnering or licensing revenue.
• Consolidation and scale - inclusion of new entities in the consolidated financials can boost reported revenue, accelerate R&D synergies, and improve operating leverage as fixed costs are spread across a broader asset base.
• Market expectations embedded in valuation - forward P/E ~17.95 implies the market is pricing in successful clinical outcomes and early monetization; failure to advance programs would likely compress multiples.
• Addressing unmet needs - focusing on therapeutic areas with few effective treatments enhances pricing power, potential for premium reimbursement, and attractiveness to strategic partners.